Distribution reappraisal of peripheral T- and NK-cell lymphoma entities through the French Lymphopath network database [0.03%]
通过法国淋巴病理网络数据库重新评估外周T细胞和NK细胞淋巴瘤的分布
Thomas Grange,Elsa Poullot,Marie Parrens et al.
Thomas Grange et al.
Analysis of volatile organic compounds in exhaled breath of blood cancer patients identifies products of lipid peroxidation as biomarkers for lymphoma detection [0.03%]
呼出气挥发性有机化合物的分析鉴定脂质过氧化产物可作为淋巴瘤检测的生物标志物
Lotte C A Stiekema,Hsuan Chou,Amy Craster et al.
Lotte C A Stiekema et al.
Current and future role of carfilzomib-based quadruplet combinations as therapy for newly diagnosed multiple myeloma [0.03%]
卡非佐米为基础的四药联合治疗在新诊断多发性骨髓瘤中的现况和前景分析
Ola Landgren,Noa Biran,Elizabeth K O&#x;Donnell et al.
Ola Landgren et al.
The treatment of newly diagnosed multiple myeloma (NDMM) has advanced rapidly in recent years, with the standard of care (SOC) now including not only triplet combinations of proteasome inhibitors (PIs), immunomodulatory agents, and steroids...
Edeghonghon Olayemi
Edeghonghon Olayemi
Editorial
HemaSphere. 2025 Jul 16;9(7):e70167. DOI:10.1002/hem3.70167 2025
Polypharmacy independently predicts survival, hospitalization, and infections in patients with lymphoid cancer [0.03%]
多重用药独立预测淋巴瘤患者生存率、住院和感染状况
Christian Brieghel,Thomas Lacoppidan,Esben Packness et al.
Christian Brieghel et al.
Polypharmacy is a result of multimorbidity and may limit treatment options in patients with lymphoid cancer (LC). To investigate the clinical impact of polypharmacy, we gathered a prediagnostic 1-year medication history from the Danish pres...
Luspatercept versus mitapivat for non-transfusion-dependent β-thalassemia: Dare to compare? [0.03%]
卢斯派替克与米塔培韦特治疗非输血依赖性β-地中海贫血：值得比较吗？
Khaled M Musallam,Sujit Sheth,Maria Domenica Cappellini et al.
Khaled M Musallam et al.
Editorial
HemaSphere. 2025 Jul 13;9(7):e70165. DOI:10.1002/hem3.70165 2025
Surface downmodulation of TIM3 safeguards healthy cells but not acute myeloid leukemia from CAR T-cell therapy [0.03%]
TIM3表面下调保护健康细胞免受CAR-T细胞治疗的影响但不会影响急性髓系白血病
Jort J van der Schans,Paresh Vishwasrao,Renée Poels et al.
Jort J van der Schans et al.
T-cell immunoglobulin and mucin-domain containing-3 (TIM3), generally known as an immune checkpoint receptor, is expressed on leukemic stem and progenitor cells (LSPCs) in acute myeloid leukemia (AML), and has an active role in LSC self-ren...
Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML [0.03%]
EPRENETAPOPT联合AZACITIDINE治疗TP53突变MDS/AML患者的长期随访及II期临床研究综合结果
David A Sallman,Rami S Komrokji,Amy E Dezern et al.
David A Sallman et al.
TP53 gene mutations (mTP53) represent a distinct molecular cohort with poor outcomes. Eprenetapopt (APR-246) is a novel, first-in-class small molecule that reactivates p53 and targets cellular redox balance, ultimately inducing apoptosis an...
PRC2-mediated apoptosis evasion is a therapeutic target of MDS/AML harboring inv(3)/t(3;3) and monosomy 7 [0.03%]
PRC2介导的逃避凋亡是染色体异常inv（3）/t（3;3）和单体7的MDS/AML的治疗靶点
Hiroyoshi Kunimoto,Ayaka Miura,Maiko Sagisaka et al.
Hiroyoshi Kunimoto et al.
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) harboring both inv(3)/t(3;3) and monosomy 7 (-7) are highly aggressive myeloid cancers of which molecular pathogenesis and therapeutic vulnerability remain elusive. High throu...
Predicting thrombotic risk in patients with classical Hodgkin lymphoma: Thro-HL multicenter study [0.03%]
经典霍奇金淋巴瘤患者血栓风险预测：Thro-HL多中心研究
Giovanni Manfredi Assanto,Eleonora Alma,Alessandro Cellini et al.
Giovanni Manfredi Assanto et al.
Thrombosis Lymphoma (ThroLy) and Khorana scores have been conceived to predict the thrombotic risk in oncohematologic patients. Currently, there is no univocal indication to perform thromboprophylaxis in classical Hodgkin lymphoma (cHL). We...